Kåre Schultz

2021

In 2021, Kåre Schultz earned a total compensation of $14.7M as President and Chief Executive Officer at Teva Pharmaceutical Industries, a 7% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,029,440
Salary$2,000,000
Stock Awards$9,999,994
Other$652,338
Total$14,681,772

Schultz received $10M in stock awards, accounting for 68% of the total pay in 2021.

Schultz also received $2M in non-equity incentive plan, $2M in salary and $652.3K in other compensation.

Rankings

In 2021, Kåre Schultz's compensation ranked 566th out of 12,405 executives tracked by ExecPay. In other words, Schultz earned more than 95.4% of executives.

ClassificationRankingPercentile
All
566
out of 12,405
95th
Division
Manufacturing
187
out of 5,494
97th
Major group
Chemicals And Allied Products
59
out of 2,369
98th
Industry group
Drugs
53
out of 2,090
98th
Industry
Pharmaceutical Preparations
31
out of 1,537
98th
Source: SEC filing on April 13, 2022.

Schultz's colleagues

We found four more compensation records of executives who worked with Kåre Schultz at Teva Pharmaceutical Industries in 2021.

2021

Sven Dethlefs

Teva Pharmaceutical Industries

Executive Vice President, North America Commercial

2021

Eric Drap

Teva Pharmaceutical Industries

Executive Vice President, Global Operations

2021

Mark Sabag

Teva Pharmaceutical Industries

Executive Vice President, International Markets Commercial

2021

Eli Kalif

Teva Pharmaceutical Industries

Chief Financial Officer

News

You may also like